Idioma:

Eccentric dosing with isosorbide-5-mononitrate in angina pectoris

Parker, John O.

The American journal of cardiology, 1993-10, Vol.72 (12), p.871-876 [Periódico revisado por pares]

New York, NY: Elsevier Inc

Texto completo disponível

Citações Citado por

Enviar para

Título:
Eccentric dosing with isosorbide-5-mononitrate in angina pectoris
Autor: Parker, John O.
Assuntos: Adult ; Aged ; Aged, 80 and over ; Angina Pectoris - drug therapy ; Angina Pectoris - physiopathology ; Antianginal agents. Coronary vasodilator agents ; Biological and medical sciences ; Cardiovascular disease ; Cardiovascular system ; Double-Blind Method ; Drug Administration Schedule ; Drug therapy ; Drug Tolerance ; Electrocardiography ; Exercise Test ; Female ; Humans ; Isosorbide Dinitrate - administration & dosage ; Isosorbide Dinitrate - analogs & derivatives ; Isosorbide Dinitrate - therapeutic use ; Male ; Medical research ; Medical sciences ; Middle Aged ; Myocardial Ischemia - drug therapy ; Myocardial Ischemia - physiopathology ; Pharmacology. Drug treatments ; Placebos ; Tablets ; Time Factors ; Vasodilator Agents - administration & dosage ; Vasodilator Agents - therapeutic use
É parte de: The American journal of cardiology, 1993-10, Vol.72 (12), p.871-876
Notas: ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
ObjectType-News-3
content type line 23
Descrição: In a placebo-controlled, parallel, double-blind study, 214 patients with stable angina were studied. Doses of 5, 10 and 20 mg of immediate-release isosorbide5-mononttrate (IS-S-MN) or placebo were administered at 0800 and 1500 hours for a period of 3 weeks. On days 1 and 14, patients underwent exercise testing before, and 2 and 7 hours after both doses; on days 7 and 21, testing was performed 2 hours after morning dosing. Study variables included total exercise duration and time to moderate angina. On day 1, the active treatment groups showed improvement over the placebo group 2 and 7 hours after dose 1, and 2 hours after dose 2. Throughout the subsequent study period, each active treatment group was superior to placebo 2 hours after the first and second doses. Only the 20 mg dose increased exercise duration 7 hours after dosing, and this was observed after both doses 1 and 2 on day 14. There were fewer episodes of angora in patients receiving the 20 mg dose. There was no increase in nocturnal angina during eccentric dosing with IS5-MN. In comparing exercise times throughout the study, tolerance did not develop during eccentric dosing. The morning exercise tests before tablet administration showed a progressive increase during the study period, with slightly greater improvement in patients receiving active therapy. This absence of a zero hour effect suggests that rebound does not occur during eccentric dosing with immediate-release IS-5-MN.
Editor: New York, NY: Elsevier Inc
Idioma: Inglês

Links

Voltar para lista de resultados

Anterior Resultado 5 Avançar Ir para próxima página

Realização: Logos de Redes Sociais:

Eccentric dosing with isosorbide-5-mononitrate in angina pectoris

Parker, John O.

New York, NY: Elsevier Inc

Buscando em bases de dados remotas. Favor aguardar.